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ABSTRACT 
Objectives: In the present study, site specific colonic drug delivery system was developed on the principles of the combination of pH and 
microbially triggered controlled system. 
Methods: The basic design consists of chitosan-chondroitin sulphate inter-polymer complex containing leflunomide. The core tablet was enteric 
coated with Eudragit E-100 so that colon specific drug release can be achieved. The leflunomide, chitosan (CH), chondroitin sulphate (ChS), 
chitosan-chondroitin sulphate inter-polymer complex (CH-ChS IPC) were characterized by Fourier Transform Infrared Spectroscopy (FT-IR). In 
vitro drug release study was conducted using sequential dissolution technique at 0.1 N HCl buffer (simulated gastric fluid), phosphate buffer pH 7.4 
(simulated intestinal fluid) and finally in phosphate buffer pH 6.8 (simulated colonic fluid) with or without rat caecal content. 
Results: FTIR studies confirmed that there was no interaction between drug and polymer. Tablets coated with Eudragit E-100 with different coat 
weights showed less than 10% of drug release in the stomach whereas same tablets showed 13.42%, 9.5%, 12.37% and 12.83% release of drug in 
phosphate buffer pH 7.4 and95.43%, 90.31%, 98.44% and 96.64% release of drug in phosphate buffer pH 6.8. Histopathology of rat colon after 
administration of Eudragit E-100 coated tablets containing chitosan-chondroitin sulphate inter-polymer complex revealed the marked reduction in 
acetic acid induced colitis in the test group.  
Conclusion: The present study confirmed that coating with Eudragit E-100 delivered the leflunomide to colon in highest efficacy with the least toxic 
effects of an anti-inflammatory therapy. 
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INTRODUCTION 
Oral drug delivery system is the most preferable route of drug 
administration due to ease of administration, patient compliance, 
flexibility in formulations etc. The oral drug delivery systems can be 
targeted to specific site in the GIT. Rationale for drug targeting is 
based on the ecosystem of specific microflora in the lower parts of 
GIT. Colonic drug delivery is a relatively new scientific area that has 
been developed during the last 10 to 15 y in almost obscurity. 
Targeting drug delivery into the colon is highly desirable for local 
treatment of the variety of bowel diseases such as inflammatory 
bowel diseases, including ulcerative colitis, Crohn’s disease, irritable 
bowel syndrome, colorectal carcinoma and constipation [1].  
The colon is having high water absorption capacity, the colonic 
contents are considerably viscous and their mixing is not sufficient, 
thus availability of most drugs to the absorptive membrane is low 
[2]. Various systems have been developed for colon specific drug 
delivery. These include, systems developed using pH-sensitive 
polymers (enteric coating polymers), time dependent release 
systems or enzymatically-controlled delivery systems. Enteric 
coatings are well-known and several marketed IBD products rely on 
them to delay release in an attempt to increase local drug delivery 
and it is possible to treat the IBD effectively by orally administering 
the drug through the colon specific drug delivery which may act 
locally as well as systemically [3]. Chitosan and chondroitin sulphate 
inter-polymer complex has already been reported to target the colon 
without undergoing any release of the drug in the upper segments of 
the GIT. Furthermore, Eudragit E-100 was selected to coat the 
tablets which is soluble only under acidic conditions at a pH equals 
to or below 5.0 and being acid soluble dissolves in acidic 
environment of the inflamed colon in inflammatory bowel diseases. 
So this polymer was selected to target the colon as it starts 
dissolving at pH 1.2 in the stomach but the tablet core partially 
coated with Eudragit E-100 prevented the drug release and 
prolonging its release while transit through the intestine, thereby, 
maintaining its effective plasma concentration over longer duration. 
Eudragit FS30D is insoluble in acidic medium but dissolves above 
pH7.0. In addition, biodegradability of both polymers could be 
expected to ensure complete release of leflunomide in the colon [4]. 
The present study is based on the development of colon targeted 
matrix tablets of leflunomide, an isooxazole containing heterocyclic 
DMRAD and immunomodulatory agent, which inhibit de novo 
pyrimidine synthesis [5]. It was investigated to target to colon 
following oral administration of the leflunomide with core 
containing CH-ChS (chitosan-chondroitin sulphate interpolymer 
complex) coated with Eudragit E-100 with reference using Eudragit 
FS30D coating. 
MATERIALS AND METHODS 
Materials 
Leflunomide was received as a gift sample from Sun Pharma (Mumbai, 
India). Chitosan and chondroitin sulphate were purchased from 
Himedia (Mumbai, India). Eudragit E-100 was procured as a gift 
sample from Panacea Biotec Ltd, Lalru. Eudragit FS30D was obtained 
from Evonic Degussa, Mumbai. All other chemicals and solvents used 
were of analytical grade. Double distilled water and triple distilled 
water was used throughout the studies (Rions, India). 
Methods 
Preparation of chitosan-chondroitin sulphate binder paste 
Binder paste of the polysaccharides was prepared by mixing the 
weighed amount of chitosan (CH) in 3% w/v solution of glacial acetic 
acid in distilled water using magnetic stirrer (IKA S22) for 30 min so 
as to enable the chitosan to swell. Weighed amount of chondroitin 
sulphate (ChS) was separately dissolved in water and was added 
slowly to this mixture. ChS solution was then slowly added to CH 
solution until homogenous solution was obtained. The mixing was 
carried out for 24 h so that proper cross-linking can take place. The 
cross-linked paste of chitosan and chondroitin sulphate was used as 
a binder for the powder mixture during wet granulation [6, 7]. 
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Fourier transform infrared spectroscopy (FT-IR) 
To characterize CH-ChS admixtures used for tablet formulation, FT-
IR spectra of leflunomide, chitosan (CH), chondroitin sulphate (ChS) 
powder and chitosan-chondroitin sulphate interpolymer complex 
(CH-ChS IPC) were measured using a FT-IR spectrophotometer 
(Shimadzu FTIT-84005) using the KBr disk method. 
Formulation of leflunomide granules and core tablet 
Accurately weighed quantities of leflunomide, lactose monohydrate 
and binder (chitosan-chondroitin sulphate 1% w/v) were physically 
mixed using a mortar and pestle to form a mass suitable for 
preparation of granules (table 1). The dough mass was passed 
through sieve # 22 to form granules and retained on # 44 sieve. 
These granules were dried at 40°C for 1 h and regranulated by 
passing again through #22 sieves and retaining on #44 sieves. The 
obtained blend was lubricated with magnesium stearate (0.25%) by 
tumbling method [8] and compressed using convex three punches, 
single station rotary compression machine (Popular Cant Laboratory 
Limited, Haryana). 
 
Table 1: Formulation ingredients for preparing leflunomide 
tablets 
S. No. Ingredients Quantity (mg) 
1 Leflunomide 20 
2 Lactose monohydrate 260 
3 Chitosan 7.5 
4 Chondroitin sulphate 7.5 
5 Magnesium stearate 5 
 
Preparation and coating of leflunomide tablets using Eudragit 
E-100 
The tablet cores were coated with acid-soluble coating material, 
Eudragit E-100. A coating solution was prepared by dissolving 10% 
(w/w) Eudragit E-100 in Isopropyl alcohol. The coating was 
performed with a conventional pan coating machine (AK Industries 
M 1107, Nakodar, India) with a tablet bed temperature of 42 °C and 
rotating speed of pan at 20 rpm. The percentage coating weight was 
5%, 7.5%, 10%, 12.5% and 15% per tablet core for formulations F1, 
F2, F3, F4 and F5, respectively [4]. 
Preparation and coating of aqueous dispersion containing 
Eudragit FS30D 
To prepare Eudragit FS30D coating dispersion, a 30% (w/w) 
aqueous Eudragit FS30D dispersion was used. Polysorbate 80 as a 
wetting agent and glyceryl monostearate as a glidant were added to 
water and the mixture was heated at 60°C by stirring for 10 min at 
50 rpm until a fine homogenous dispersion was obtained. After 
cooling, this dispersion was gently added to Eudragit FS30D 
dispersion and mixed by magnetic stirrer [9]. 
The coating was performed with a conventional pan coating machine 
(AK Industries M1107, Nakodar, India) with a tablet bed 
temperature of 42 °C and rotating speed of pan at 20 rpm. The spray 
rate and the bed temperature during the coating process were 2 
g/min and 30-35 °C, respectively [4, 9]. Before coating the tablets 
were preheated to 40 °C bed temperatures for 15 min. The tablets 
were coated to 5%, 7.5%, 10%, 12.5% and 15% total weight gain.  
Evaluation of physical parameters 
The blend for the preparation of tablets was evaluated before the 
compression for parameters like an angle of repose, percentage 
compressibility, Carr’s Consolidation Index (CI) and Hausner’s Ratio 
(HR). The tablets were evaluated for all the parameters like 
hardness, surface appearance, size measurement, friability, content 
uniformity, weight variation and disintegration [10]. 
In vitro drug release studies 
To simulate the gastrointestinal transit conditions, uncoated and 
coated leflunomide tablets were subjected to different dissolution 
media. In vitro drug release studies were carried out using USP Type 
II (basket method) Apparatus (Lab India DISSO 2000, India) 
maintained at the temperature of 37 ± 0.5°C with constant stirring 
rate of 50 rpm. The uncoated as well coated tablets prepared using 
CH-ChS IPC as binder were evaluated for drug release by sequential 
exposure to HCl buffer pH 1.2 (700 ml) for 2 h, Phosphate buffer pH 
7.4 (770 ml) for 3 h and finally in Phosphate buffer pH 6.8 (800 ml) 
for 19 h [11]. 
Drug release studies in presence of rat caecal content 
Preparation of simulated colonic fluid 
To assess the vulnerability of chitosan-chondroitin sulphate 
interpolymer complex being acted upon by colonic bacteria, drug 
release studies were carried out in the presence of rat caecal 
contents, because of its similarity with human intestinal microflora, 
in order to induce the enzyme that specifically acts on chitosan-
chondroitin sulphate interpolymer complex in the caecum. Male 
Wister rats weighing 140-160g were used. Thirty minutes before the 
commencement of the drug release studies, two rats were sacrificed 
by spinal traction. The abdomen was opened and isolated, ligated at 
both ends, cut loose, and transferred into phosphate buffer pH 6.8, 
previously bubbled with CO2
In vitro drug release studies in the presence of rat caecal 
content 
. The rat caecal bags were opened, their 
contents were weighed and 4% w/v solution of rat caecal contents 
was prepared in pH 6.8 phosphate buffer [12]. 
In vitro release studies were carried out using USP Type II (basket 
method) Apparatus (Lab India DISSO 2000, India) maintained at 
temperature of 37 ± 0.5°C with constant stirring rate of 50 rpm with 
slight modifications. After five hours, the studies were carried out 
using 100 ml of 4% w/v rat caecal content medium in phosphate 
buffer pH 6.8 (simulated colonic fluid). At specific time intervals, 5 
ml of the samples were withdrawn from each dissolution vessel at 
regular intervals and replaced with equal volume of respective fresh 
dissolution medium. Amount of drug released was determined by 
UV-Visible Spectrophotometer (Blue Star AU-2701) employing 
wavelength of 260 nm for both acidic and basic conditions [11]. 
Pharmacodynamic studies 
Induction of colitis in rat 
In order to study the ameliorating effect of leflunomide on the 
inflamed tissue of colon in inflammatory bowel diseases, Acetic acid 
model was selected which is simple and reproducible [13]. 
Moreover, it is most relevant model and valuable for studying early 
events of inflammation after mucosal injury. Mucosal and 
submucosal inflammation followed initial injury and was associated 
with activation of arachidonic acid pathways. 
Induction of inflammation 
The procedure was approved by Institutional Animal Ethics 
Committee, Guru Nanak Dev University, Amritsar. Wistar Rats 
(average weight 140-160g, n=3/group) undergoing fasting (fasted 
23 h before experimentation) were used and allowed food and water 
after the administration of acetic acid (2 ml of 4% acetic acid in 
saline). To induce an inflammation, all groups were treated with 
acetic acid except for the healthy control. The rats were catheterized 
8 cm intrarectal, after anaesthised with ketamine and 2 ml of 4% 
acetic acid in saline was injected into colon via butterfly cannula. 
Animals were then maintained in a vertical position for 45 s 
followed by washing with 0.9% saline and returned to their cages. 
For 24 h the rats were housed without treatment to maintain the 
development of a full inflammatory bowel disease model. The 
animals of standard and test groups received orally uncoated and 
coated leflunomide tablets. The animals of all groups were examined 
for 24 h for rectal bleeding. 
Histopathological studies 
The colon was excised and immediately immersed in 10% buffered 
formalin. The extent of colonic damage was scored as described by 
Elson et al. [13]. Normal histological appearance (score 0); 
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histological damage limited to the surface epithelium (score 1); focal 
ulceration and cell disruption limited to mucosa (score 2); focal, 
trans-mural inflammation and ulceration (score 3); extensive trans-
mural ulceration and inflammation bordered by areas of normal 
mucosa (score 4); extensive trans-mural ulceration and 
inflammation involving entire section from epithelium to serosa 
(score 5). 
RESULTS AND DISCUSSION 
Evaluation of preparation method 
Angle of Repose, Carr’s Consolidation Index (CI) and Hausner’s Ratio 
(HR) are indicative of the relative flow rate, cohesiveness and 
particle size of granules. The angle of repose was 31° indicating the 
satisfactory flow behavior of the granules. Hausner’s Ratio was 1.02 
and Carr’s Index was 12 indicating the optimum flowability and 
compressibility of the granules. However, the yield of tablets 
produced was optimum in all the tablet batches (A, B, C, D and E) as 
shown in table 3. 
The leflunomide coated tablets used for experimental animals were 
evaluated as per the Pharmacopoeial tests and all the prepared batches 
were found to be within limits (table 3). The tablets were found to show 
0.27-0.45% w/w friability.  
Hence, the tablets passed the USP Friability test. The tablets passed the 
content uniformity test as the acceptance value obtained was 5.40% 
which is less than the maximum 15% USP tolerance limit. The 
disintegration time for the coated tablets was observed to be 2h in HCl 
buffer pH 1.2, 3 h in phosphate buffer pH 7.4 and 19 h in phosphate 
buffer solution pH 6.8 [10]. 
 
Table 2: Physical evaluation of lefunomide granules 
Batch code Angle of repose (deg) mean±SD %Carr’s Consolidation Index mean±SD Hausner’s Ratio mean±SD 
A 27.0±1.10 12.0±0.50 0.94±0.24 
B 30.0±0.80 12.3±0.50 1.02±0.01 
C 27.0±0.90 12.2±1.10 1.05±0.06 
D 29.0±0.60 11.1±0.60 1.00±0.54 
E 31.0±1.20 12.0±1.20 1.00±0.40 
 























A  34.13±0.36 2.19±0.04 4.60±0.42 5.5±0.10 6.50±0.45 0.25±0.01 5.30±0.56 
B  33.98±0.42 2.18±0.05 4.49±0.38 5.7±0.20 7.23±0.12 0.27±0.07 5.29±0.75 
C  34.10±0.85 2.21±0.08 4.51±0.45 6.1±0.40 6.23±0.14 0.29±0.03 5.55±0.57 
D  34.56±0.37 2.33±0.02 4.61±0.37 5.6±0.40 5.78±0.41 0.23±0.04 5.59±0.36 
E  33.99±0.64 2.17±0.01 4.59±0.32 6.1±0.30 6.00±0.12 0.22±0.04 4.68±0.76 
 
Fourier transforms Infrared Spectroscopy (FT-IR) analysis  
In the FT-IR spectra of leflunomide and chitosan-chondroitin 
sulphate interpolymer complex (CH-ChS IPC), the absorption peak at 
3355 cm-1 (N-H stretch) was obtained and showed it was found to be 
intact. Similarly, the peaks at 1691 cm-1 and 1606 cm-1
Further, the peaks at 1253 cm
 confirmed 
that there was no interaction between the drug and the chitosan-
chondroitin sulphate interpolymer complex.  
-1and 1407 cm-1were obtained. It 
suggested the formation of carboxylate linkages between–COO¯ 
chondroitin sulphate and–NH4+
 
of chitosan. The FTIR spectra of the 
pure drug as well as CH-ChS IPC indicated that no chemical 
interaction occurred between leflunomide and the polymers used 
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Fig. 1: FT-IR spectra of (A): chitosan; (B): chondroitin sulphate; 
(C): chitosan-chondroitin sulphate complex; (D): leflunomide 
chitosan-chondroitin sulphate interpolymer complex 
 
In vitro drug release studies 
The drug release profile of leflunomide from uncoated tablets and 
Eudragit E-100 coated tablets prepared using different coat weights 




Fig. 2: Cumulative drug release profile from uncoated tablets 
 
It is evident from the fig. 2 that leflunomide uncoated tablets 
released only 37 % of leflunomide in the first 2 h of dissolution 
studies indicating their ability to minimize the amount of drug 
release in the physiological environment of stomach.  
The obtained results can be explained as when leflunomide uncoated 
tablets come into contact with the acidic dissolution medium, they 
take up water and swell, forming a gel layer around the tablet, thus 
inhibiting the drug release[14, 15]. The release of leflunomide from 
uncoated tablets was rapid and significantly higher than that 
observed for coated tablets (p<0.05). 
To overcome the problem of drug release in the acidic pH, 
leflunomide uncoated tablets were coated with different coat 
weights of Eudragit E-100. It has been reported that 
The time required for releasing approximately 37% leflunomide 
from tablets coated with Eudragit E-100 with different coat weights 
in F1, F2, F3, F4 and F5 was 5 h, 6 h, 8 h, 6 h and 7 h, respectively 
(fig. 3). All the batches except F1 were observed to release less than 
10% of the leflunomide in the simulated gastric fluid, thus, 
complying with USP standards. Hence, the observed drug release 
indicated that the tablets coated with Eudragit E-100 in F2, F3, F4 
and F5 complied with enteric release requirements while those 
coated in F1 did not exhibit enteric release compliance [17]. 
during an acute 
attack of inflammatory bowel disease, the pH of the colon lumen 
often decreases significantly. This pathological drop in the luminal 
pH of the colon favors the development of a coated dosage form with 
the acid-soluble coating film of Eudragit E-100 to achieve drug 
delivery to colon using cross-linked chitosan (CH) and chondroitin 
sulphate (ChS) complex as a binder in the tablet core [16]. 
 
 
Fig. 3: Cumulative drug release profile from E-100 coated 
tablets 
 
A drug release of 80.87% was observed with uncoated tablets in 
phosphate buffer 7.4 and 98.99% in phosphate buffer pH 6.8. Also 
tablets coated with E-100 having the weight gain of 7.5%, 10%, 
12.5% and15% w/w in formulation F2, F3, F4 and F5, respectively, 
showed 13.42%, 9.5%, 12.37% and 12.83% release of leflunomide in 
pH7.4 phosphate buffer and similarly 95.43%, 90.31%, 98.44% and 
96.64% release of leflunomide in phosphate buffer pH6.8. The pH in 
the GIT changes from pH 1.2 (stomach) to pH 7.4 (small intestine) 
and finally to pH 6.8 (colon).  
Therefore, colon release dosage forms should ideally be tested by 
sequentially subjecting them to pH 1.2, pH 7.4 and to pH 6.8 finally. 
To simulate the GIT environment, dissolution studies were 
conducted by sequentially exposing the tablets to phosphate buffer 
pH 7.4 for 3 h and phosphate buffer pH 6.8 for 19 h. Further, 
 
drug 
release studies of F4 were carried out with intestinal pH maintained 
at 4.0 (fig. 4). It shows more specific results and exhibits minimum 
drug release in upper regions of GIT in order to provide targeted 




4: Comparative drug release profile from Eudragit E-100 at 
pH 6.8 and pH 4.0 at 12.5% w/w gain 
As the formulation F4 with 12.5% coat weight released maximum 
amount of drug in 24 h so this was selected for further comparison 
with Eudragit FS30D which has been successfully used to release the 
drugs to colon [18]. The tablets were coated with Eudragit FS30D 
with the weight gain of 12.5% w/w in formulation F6 (fig. 5).  
The tablets were coated with Eudragit FS30D with the weight gain of 
12.5 % w/w in formulation F6. 
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Fig. 5: Comparative drug release profile from Eudragit E-100 
and Eudragit FS30D coated tablets with weight gain of 
12.5%w/w 
 
Drug release rate could be expected to increase in vivo as a result 
of biodegradation of polysaccharides by the bacteria present in 
colon. Many studies have reported that the drug release in rat 
caecal content could be increased to the two or fourfold of its 
value in presence of the colonic bacteria [19]. Based on this 
consideration, formulation for colon target that showed the 
slowest drug release in vitro would show a reasonable sustained 
release in vivo. Therefore, in order to know the behavior of core 
containing CH-ChS IPC, the release study of the formulations F4 
and F6 was further carried out by adding rat caecal content as 
shown in fig. 6. 
As Eudragit E-100 starts dissolving at pH 1.2, a drug release of 
47% was observed from formulation F4 in 6 h and almost 80% of 
drug was released at 8th hour from the same indicating complete 
erosion of the film by that time after adding the rat caecal 
contents. As the CH-ChS complex erodes slowly in phosphate 
buffer pH 7.4, thereby suppressing the initial drug release in 
upper segments if GIT, the drug core started swelling and 
released the drug proportionately above pH 6.5 but as on adding 
rat caecal content (fig. 6) there was the abrupt release of the 
leflunomide from the core indicating the polysaccharides are 
degraded by colonic bacterial species.  
The results of the histopathological studies revealed no sign of colitis or 
epidermal damage in healthy group I (fig. 7A). Colitis control group II 
shows mucosal injury characterized by congestion of blood vessels with 
margination of neutrophils and immigration of neutrophils, submucosal 
hemorrhage, transmural inflammation and ulcerated mucosa at some 
places (fig. 7B). The groups III receiving uncoated leflunomide tablets 
showed slight recovery from mucosal abscess and inflammatory 
infiltrate and transmural inflammation was not seen (fig. 7C). 
However, there have been many reports where IPC has been found 
to be digested by the microflora of the colon. Hence, the ability of 




Fig. 6: Comparative drug release profile from Eudragit E-100 
and Eudragit FS30 Dcoated tablets with weight gain of 
12.5%w/w in rat caecal content 
  
The test group 1V receiving Eudragit E-100 coated tablets showed 
no mucosal injury, slight epithelium recovery and slight 
inflammatory infiltration and mucosa was intact but slight 
inflammation was seen in mucosa (fig. 7D). The test group V 
receiving Eudragit FS30D coated tablets also showed no mucosal 
injury and inflammatory infiltration indicating full recovery from 
acetic acid induced colitis after 24 h (fig. 7E). Table 4 depicts the 
evaluation of colonic damage. 
 
Table 4: Evaluation of colonic damage 
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Fig. 7: (A): Histopathology of the healthy rat colon; (B): Histopathology of acetic acid induced colitis; (C): Histopathology of acetic acid 
induced colitis treated with uncoated tablets; (D): Histopathology of acetic acid induced colitis treated with Eudragit E-100 tablets; (E): 
Histopathology of acetic acid induced colitis treated with FS30D 
 
CONCLUSION 
In the present investigation, CH-ChS IPC containing 
1. Watts PJ, Illum L. Colonic drug delivery and opportunities. 
Indian J Pharm Sci 1997;23:893-913. 
leflunomide in 
the core was investigated for inflammatory bowel disorder. The 
tablets were further coated with Eudragit E-100 in order to target it 
to the colon and prevent the release of the drug through its transit to 
the colon. Uncoated and coated leflunomide tablets were subjected 
to in vitro dissolution studies by sequentially exposing them to 
different buffers (with and without rat caecal contents). The 
formulation releasing maximum amount of drug in 24 h during 
dissolution studies was further compared with the tablets coated 
with Eudragit FS30D which is taken as a standard coating agent for 
colon targeting. Histopathological studies were carried out using 
acetic acid induced colitis in rats following oral administration of 
uncoated leflunomide tablet, Eudragit E-100 coated tablets and 
EudragitFS30D coated tablets containing CH-ChS IPC in the tablet 
core. It was seen that the mucosa was intact, transmural 
inflammation was not visible and there was just mild inflammation 
in the mucosa. Hence, coating with Eudragit E-100 delivered the 
leflunomide to colon in highest efficacy with the least toxic effects of 
an anti-inflammatory therapy. 
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